Stephens Consulting’s Zevra Therapeutics ZVRA Stock Holding History

Stephens Consulting’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,000	Closed	-$6.94K	–	547
2024 Q3	$6.94K	Hold	1,000	–	–	﹤0.01%	370
2024 Q2	$4.9K	Sell	1,000 -1,000	-50%	-$4.74K	﹤0.01%	407
2024 Q1	$11.6K	Hold	2,000	–	–	﹤0.01%	297
2023 Q4	$13.1K	Hold	2,000	–	–	﹤0.01%	285
2023 Q3	$9.64K	Hold	2,000	–	–	﹤0.01%	314
2023 Q2	$10.2K	Hold	2,000	–	–	﹤0.01%	307
2023 Q1	$11K	Hold	2,000	–	–	0.01%	306
2022 Q4	$9.18K	Hold	2,000	–	–	0.01%	311
2022 Q3	$12.5K	Hold	2,000	–	–	0.01%	296
2022 Q2	$8.92K	Hold	2,000	–	–	0.01%	342
2022 Q1	$10.1K	Sell	2,000 -225	-10%	-$1.43K	0.01%	352
2021 Q4	$19.4K	Buy	+2,225	New	+$19.9K	0.02%	297

Other funds holding ZVRA

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stephens Consulting's ZVRA Position: Q4 2024 in Review

Stephens Consulting sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 1,000 shares — an estimated $6.94K sold.

Stephens Consulting first reported a position in ZVRA in Q4 2021 and held it in 12 quarters. The position peaked at $19.4K in Q4 2021. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

Stephens Consulting reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
Stephens Consulting sold 1,000 Zevra Therapeutics shares in Q4 2024, an estimated $6.94K.
Stephens Consulting first reported a position in Zevra Therapeutics in Q4 2021 and held it in 12 quarters.
Stephens Consulting's Zevra Therapeutics position peaked at $19.4K in Q4 2021.
109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Stephens Consulting's 13F filing for Q4 2024, filed 27 Jan 2025.